Sacubitril, Valsartan combo effective in high risk heart failure patients: Circulation

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-02-22 05:00 GMT   |   Update On 2023-10-13 10:32 GMT

CAPTION

Novel biomarkers predict the development of incident heart failure.

CREDIT

MostPhotos/Rossella Apostoli.

Advertisement

USA: Treating high-risk patients hospitalized for acute decompensated heart failure with sacubitril/valsartan reduces the risk of CV death or re-hospitalization for heart failure, show results from the PIONEER-HF study. The findings of the study are published in the journal Circulation: Heart Failure.

Initiation of sacubitril/valsartan versus enalapril in patients stabilized during hospitalization for acute decompensated HF decreases the risk of rehospitalization for HF or cardiovascular (CV) death without increasing the risk of adverse events. Whether potentially high-risk subpopulations have a similar risk-benefit profile is not known.

Advertisement

Against this background, David D. Berg, Harvard Medical School, Boston, MA, and colleagues performed PIONEER-HF (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP [N-terminal pro-B type natriuretic peptide] in Patients Stabilized From an Acute HF Episode). PIONEER-HF was a multicenter, randomized, double-blind trial of in-hospital initiation of sacubitril/valsartan (n=440) versus enalapril (n=441) in patients stabilized during hospitalization for acute decompensated HF.

The composite of rehospitalization for HF or cardiovascular death was adjudicated. Safety outcomes included symptomatic hypotension, worsening renal function, and hyperkalemia.

The researchers evaluated heterogeneity in the effect of sacubitril/valsartan on these safety in selected subgroups of clinical concern -- patients with baseline systolic blood pressure ≤118 mm Hg (median; n=448), baseline NT-proBNP >2701 pg/mL (median; n=395), estimated glomerular filtration rate <60 mL/minute per 1.73 m2 (n=455), ≥1 additional hospitalization for HF within the prior year (n=343), admission to the ICU during the index hospitalization (n=96), inotrope use during the index hospitalization (n=68), and severe congestion (n=219). 

Key findings of the study include:

  • The relative risk reduction in cardiovascular death or rehospitalization for HF with sacubitril/valsartan versus enalapril was consistent across all high-risk subgroups.
  • The risks of worsening renal function, symptomatic hypotension, and hyperkalemia with sacubitril/valsartan versus enalapril were also consistent in each high- versus low-risk subgroup.

"In high-risk subpopulations admitted for acute decompensated HF, treatment with sacubitril/valsartan after initial stabilization conferred a consistent reduction in cardiovascular death or rehospitalization for HF and was well tolerated," concluded the authors. 

The study titled, "Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial," is published in the journal Circulation: Heart Failure.

DOI: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.120.007034


Tags:    
Article Source : Circulation: Heart Failure

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News